HomeCompareFAXRF vs JNJ

FAXRF vs JNJ: Dividend Comparison 2026

FAXRF yields 3.90% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FAXRF wins by $6.48M in total portfolio value
10 years
FAXRF
FAXRF
● Live price
3.90%
Share price
$13.50
Annual div
$0.53
5Y div CAGR
69.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.51M
Annual income
$5,193,030.64
Full FAXRF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — FAXRF vs JNJ

📍 FAXRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFAXRFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FAXRF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FAXRF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FAXRF
Annual income on $10K today (after 15% tax)
$331.88/yr
After 10yr DRIP, annual income (after tax)
$4,414,076.04/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, FAXRF beats the other by $4,410,090.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FAXRF + JNJ for your $10,000?

FAXRF: 50%JNJ: 50%
100% JNJ50/50100% FAXRF
Portfolio after 10yr
$3.27M
Annual income
$2,598,860.02/yr
Blended yield
79.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

FAXRF
Analyst Ratings
3
Buy
Consensus: Buy
Altman Z
0.8
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FAXRF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFAXRFJNJ
Forward yield3.90%2.13%
Annual dividend / share$0.53$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR69.7%28%
Portfolio after 10y$6.51M$30.3K
Annual income after 10y$5,193,030.64$4,689.40
Total dividends collected$6.37M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: FAXRF vs JNJ ($10,000, DRIP)

YearFAXRF PortfolioFAXRF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,363$662.60$10,592$272.30+$771.00FAXRF
2$13,352$1,194.06$11,289$357.73+$2.1KFAXRF
3$16,512$2,225.32$12,123$472.89+$4.4KFAXRF
4$22,032$4,364.59$13,141$629.86+$8.9KFAXRF
5$32,811$9,236.43$14,408$846.81+$18.4KFAXRF
6$56,923$21,815.28$16,021$1,151.60+$40.9KFAXRF
7$120,932$60,024.27$18,122$1,588.22+$102.8KFAXRF
8$331,642$202,244.76$20,930$2,228.20+$310.7KFAXRF
9$1,234,494$879,636.96$24,792$3,191.91+$1.21MFAXRF
10$6,513,939$5,193,030.64$30,274$4,689.40+$6.48MFAXRF

FAXRF vs JNJ: Complete Analysis 2026

FAXRFStock

Fairfax Financial Holdings Limited, through its subsidiaries, provides property and casualty insurance and reinsurance, and investment management services in the United States, Canada, Asia, and internationally. The company operates through Insurance and Reinsurance, Run-off, and Non-Insurance Companies segments. It insures against losses to property from fire, explosion, earthquake, windstorm, flood, boiler explosion, machinery breakdown, and construction defects, as well as underwrites automobile, commercial and personal property, and crop insurance. The company also offers workers' compensation, employer's liability, accident and health, medical malpractice, professional liability, and umbrella coverage insurance products; marine, aerospace, surety risk, and other risks and liabilities insurance products; and reinsurance products. In addition, it retails home improvement goods, toys and baby products, golf equipment, sports apparel and accessories, housewares and home décors, and tableware and gifts; invests in retail business; and owns and operates holiday resorts. Further, the company provides integrated travel and travel-related financial services; originates, processes, and distributes pulses and staple foods; creates, produces, and distributes entertainment content; and provision of pet medical insurance and database services, as well as media and marketing solutions. The company was formerly known as Markel Financial Holdings Limited and changed its name to Fairfax Financial Holdings Limited in 1987. Fairfax Financial Holdings Limited was incorporated in 1951 and is headquartered in Toronto, Canada.

Full FAXRF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this FAXRF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FAXRF vs SCHDFAXRF vs JEPIFAXRF vs OFAXRF vs KOFAXRF vs MAINFAXRF vs ABBVFAXRF vs MRKFAXRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.